|
Market Closed -
NYSE
04:00:00 2026-09-04 pm EDT
|
5-day change | 1st Jan Change | ||
| 3.130 USD | +0.32% |
|
-0.95% | +13.82% |
| Aug. 19 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| Aug. 14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 357.3 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 74.78% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 190.7 | 126.4 | 194.8 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 211.36% | -33.71% | 54.05% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -3.13x | -2.97x | -3.09x |
| PBR | - | - | - | 0.78x | 0.99x | 1.51x | 1.46x | 1.7x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -0.56x | 0.79x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 1,065x | 902x | 386x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 569x | 319x | 211x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.53x | -0.91x | -1.35x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.54x | -0.89x | -1.3x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.71x | -0.88x | -1.29x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -58.3% | -113% | -77.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.001 | -1.053 | -1.012 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.3355 | 0.3962 | 0.9246 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -124.5 | -139 | -144.5 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -123.9 | -142.3 | -149.9 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -115.6 | -135.3 | -142.8 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -166.6 | -230.9 | -162.5 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 3.130 | 3.130 | 3.130 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,152 | - | - |
| Announcement Date | 9/21/21 | 5/1/23 | 3/28/24 | 3/26/25 | 3/16/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.13x | 568.6x | -1.53x | -.--% | 357M | |
| 32.76x | 5.88x | 17.63x | 0.99% | 48.41B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.43x | 29.72x | -.--% | 40.73B | |
| 28.26x | 8.5x | 21.55x | 0.4% | 33.21B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 23.87x | 2.08x | 9x | 1.13% | 14.45B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 28.05x | 94.34x | 12.03x | 0.28% | 28.5B | |
| Weighted average by Cap. | 27.09x | 48.23x | 12.19x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
